Pacira Defends EXPAREL IP Strategy Against Activist Claims Amidst Proxy Battle

summarizeSummary

Pacira BioSciences issued additional proxy materials, refuting activist investor DOMA Perpetual's claims about its intellectual property strategy and urging shareholders to vote for its board nominees.

check_boxKey Events · Corporate Governance and Compliance · PCRX

• Defends IP Strategy

  Pacira issued a press release to set the record straight regarding DOMA Perpetual's 'misleading statements' about its intellectual property strategy, emphasizing DOMA's lack of understanding of the biopharmaceutical industry.

• Highlights Strong Patent Estate

  The company asserts the EXPAREL franchise is strong, protected by 21 Orange Book listed patents across two families, including a new '940 patent family providing protection into July 2044.

• Addresses Generic Challenges

  Pacira clarified that recent Paragraph IV generic challenges only mean ANDAs have been filed, not that generic challengers have FDA-approvable products, and highlighted the significant hurdles generic filers must overcome.

• Urges Shareholder Vote

  Pacira reiterated its call for stockholders to vote 'FOR' its highly qualified nominees on the BLUE proxy card for the 2026 Annual Meeting of Stockholders.

auto_awesomeAnalysis · PCRX · Life Sciences

This filing is part of an ongoing proxy battle with activist investor DOMA Perpetual. Pacira is defending its intellectual property strategy, particularly for its key EXPAREL franchise, against DOMA's criticisms. The outcome of this proxy contest will determine the composition of Pacira's board and could influence future strategic direction, including how the company manages its critical patent portfolio and responds to generic challenges.